



Financial tear sheet

Corporate Profile

2015 was a pivotal year for Baxter: In July we executed the spinoff of our BioScience business. The corporate separation created value for investors and resulted in a Baxter portfolio focused solely on the Hospital Products and Renal technologies central to our core identity. Today we are collaborating around the world to shape a leaner, more efficient company, positioned to deliver on our mission and succeed on behalf of all our stakeholders well into the future.

Stock Information

| | |
|----------------------------------|------------------|
| BAX (BAX) | |
| Exchange | NYSE (US Dollar) |
| Price | \$60.69 |
| Change (%) | ▼ 0.29 (0.48%) |
| Volume | 2,547,013 |
| 52 Week Low | \$42.22 |
| Market Cap | \$32,995,278,529 |
| Rolling EPS | 3.36 |
| PE Ratio | 18.1727 |
| Shares Outstanding | 543,669,114 |
| Data as of 06/27/2017 4:00 PM ET | |



Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest News

| DATE | TITLE |
|----------|--|
| 06/26/17 | Baxter Announces DoseEdge Bi-Directional Integration with Epic in the Pharmacy |
| 06/14/17 | Baxter Announces Agreement with Dorizoe Lifesciences to Further Expand Generic Injectables Pipeline |
| 06/07/17 | Baxter Announces U.S. FDA Approval and Commercial Launch of Ready-to-Use Clindamycin Injection in Saline |

Recent & Upcoming Events

| DATE | TITLE |
|------------------------|--|
| 05/02/2017 9:00 AM CT | Baxter's Annual Meeting of Stockholders |
| 05/16/2017 10:00 AM PT | Bank of America Merrill Lynch Healthcare Conference Location Las Vegas |
| 05/23/2017 9:00 AM ET | UBS Global Healthcare Conference Location New York, NY |

SEC Filings

| FILING DATE | FORM |
|-------------|----------|
| 06/06/17 | 4 |
| 06/06/17 | 4 |
| 06/02/17 | 4 |
| 06/02/17 | SC 13D/A |

Primary IR Contact

Clare Trachtman
Baxter International Inc.
Phone: 224-948-3085